IP Library Granted Patent US 8,408,200
Granted Patent B2
US 8,408,200 · App. 09/414,384 · Granted Apr 2, 2013

Flow resistance modulated aerosolized active agent delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,408,200
App. No.
09/414,384
Granted
Apr 2, 2013
Kind
B2
Abstract

The present invention is directed to methods and devices for delivering an active agent formulation to the lung of a human patient. The active agent formulation may be in dry powder form, it may be nebulized, or it may be in admixture with a propellant. The active agent formulation is delivered to a patient at a low inspiratory flow rate for an initial period of time to increase bioavailability of the active agent.

Claims (16)

1. A device for controlling the delivery of an aerosolized active agent to the lungs of a human patient, said device comprising a valve that provides a high flow resistance of at least 0.4 (cm H 2 O) 1/2 /SLM in the inhalation direction at the onset of the patient's inhalation and that subsequently opens during the inhalation to provide a lower flow resistance, wherein the lower flow resistance allows for a higher flow rate through the device.

2. A device according to claim 1 wherein the high flow resistance is a resistance of between 0.4 and 2 (cm H 2 O) 1/2 /SLM.

3. The device of claim 1 wherein the lower flow resistance is a resistance between 0 and 0.3 (cm H 2 O) 1/2 /SLM.

4. The device of claim 1 wherein the high flow resistance corresponds to a flow rate of 15 liters per minute or less.

5. The device of claim 1 wherein the lower flow resistance corresponds to a flow rate of 15-80 liters per minute.

6. The device of claim 1 wherein the high flow resistance is provided for an initial time period of less than 10 seconds.

7. The device of claim 1 wherein the high flow resistance is provided for an initial time period of less than 5 seconds.

8. A device for controlling the delivery of an aerosolized active agent to the lungs of a human patient, said device comprising a valve that provides a high flow resistance in the inhalation direction at the onset of the patient's inhalation and which corresponds to a flow rate of about 15 liters per minute or less and that subsequently opens during the inhalation to provide a lower flow resistance which corresponds to a higher flow rate.

9. The device of claim 8 wherein the lower flow resistance corresponds to a flow rate of between about 15 and 80 liters per minute.

10. The device of claim 8 wherein the high flow resistance is a resistance of between about 0.4 and 2 (cm H 2 O) 14 /SLM.

11. The device of claim 8 wherein the high flow resistance is provided for an initial time period of less than about 10 seconds.

12. A device for controlling the delivery of an aerosolized active agent to the lungs of a human patient, said device comprising a valve that is adapted to provide a first flow resistance in the inhalation direction at the onset of the patient's inhalation and that subsequently opens during the inhalation to provide a second flow resistance, the second flow resistance being less than the first flow resistance, wherein the second flow resistance allows for a higher flow rate.

13. The device of claim 12 wherein the first flow rate is provided for an initial time period of less than about 10 seconds.

14. The device of claim 12 wherein the first flow rate is less than about 15 liters per minute.

15. The device of claim 14 wherein the second flow rate is between about 15 and 80 liters per minute.

16. The device of claim 12 wherein the first flow resistance provides a first flow rate and wherein the second flow resistance provides a second flow rate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2013
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 029602/0387 →
ASSIGNMENT OF PATENT RIGHTS Recorded Jan 7, 2009
From: NEKTAR THERAPEUTICS
To: NOVARTIS PHARMA AG
Reel/Frame 022071/0001 →